Drug Trial Radar · NCT07325136
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Feb 3, 2026
Primary completion
Apr 23, 2029
Study completion Apr 24, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Conditions
- Relapsed/Refractory Small Cell Lung Cancer
Interventions
BMS-986525Drug
Specified dose on specified days
PumitamigDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years
- Number of participants with serious adverse events (SAEs)Time frame: Up to approximately 2 years
- Number of participants with AEs meeting dose-limiting toxicity (DLT) criteriaTime frame: Up to 21 days
- Number of participants with AEs leading to discontinuationTime frame: Up to approximately 2 years
- Number of participants with AEs leading to deathTime frame: Up to approximately 2 years
Locations
13 sites in 6 countries. Site status is shown where the registry gives one.
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Local Institution - 0029
Beijing, Beijing Municipality, China · Not yet recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Istituto Clinico Humanitas
Rozzano, Milano, Italy · Recruiting
Local Institution - 0020
Hirakata, Osaka, Japan · Not yet recruiting
Local Institution - 0018
Chuo-ku, Tokyo, Japan · Not yet recruiting
Centrul de Oncologie Sf. Nectarie SRL
Craiova, Romania · Recruiting
Oncohelp Medical Center
Timișoara, Timiș County, Romania · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.